Steatotic liver disease (SLD) is the most common liver disease worldwide and a leading cause of liver-related morbidity and mortality. Current prevalence of SLD is approximately 30 % of the global population with an incidence of 4.6 per 100 patient years [1]. Fibrosis stage is the most important determinant of complications and mortality in case of SLD [2]. Common genetic variants such as PNPLA3, TM6SF2 and HSD17B13 are disease modifiers that influence prevalence and risk of fibrosis progression.
